"The price of greatness is responsibility." Sir Winston Churchill


Search the IBPA



IBPA Issues
About IBPA
IBPA Constitution
FAQ-s
IBPA Events
Individual Membership
Institutional Membership
IBPA Forums / Groups
Cooperation with IBPA
Links

Publications
IBPA Careers Newsletter
Past Issues
Industry Publications
Promote Yourself within the Industry
Submit Your Article

Career Center: Employers
Job Posting
Free Resume Database
Volunteers Database

Career Center: Job Seekers
Now Hiring
Submit Resume
Career Training
Nurses Careers in Biopharm
Scholarship Programs
Internship Programs
Resume Editing & Interview Coaching
Volunteer for the Industry
Download IBPA Career Info Brochure

Industry Directories and Listings
Pharmaceutical Companies
Contract Research Organizations
Professional Associations
Recruiters and Staffing Agencies
Clinical Research Centers
Consulting Companies
Education & Training Institutions
Jobs and Resume Searching Directories
Research and Development Companies
List Your Company

Investor's Center
Offers
Calls

Contact IBPA
US Chapter
Canadian Chapter
European Chapter
Asian Chapter

Start Your Career in Biotech with IBPA Scholarship Programs
Untitled Document



Subscribe to our "Careers in the Biopharmaceutical Industry" newsletter:

Name*:

Email*:

City:

Country:

Phone:

To unsubscribe, click here

 

 

Black box warning

From Wikipedia, the free encyclopedia

 

In the United States, a black box warning is a type of warning that appears on prescription drugs that may cause serious adverse effects. It is so named for the black border that usually surrounds the text of the warning.

A black box warning means that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects. The U.S. Food and Drug Administration (FDA) can require a pharmaceutical company to place a black box warning on the labeling of a prescription drug, or in literature describing it. It is the strongest warning that the FDA requires.

Black box warnings on drugs have received increased media attention in the United States in 2005. Among some of the more widely covered stories:

  • The FDA has required that black box warnings be placed on all antidepressant medications warning they may result in increased risk of suicidal tendencies in children and adolescents.
  • FDA advisors have recommended that Pfizer be required to place a black box warning on their NSAID celecoxib (Celebrex®).
  • As of 17 November 2004, the FDA has required a black box warning on the Depo-Provera contraceptive injection, due to the risk of significant loss of bone density with long-term use. [1]


External links




Learn More About the Biopharmaceutical Industry and Clinical Research:


Category:


Powered by Wikipedia, the free encyclopedia. Articles were developed by IBPA volunteers.

A

B

C

D

E

F

G

I

K

L

M

N

P

Q

R

S

T


©2004 International Biopharmaceutical Association Inc., all rights reserved
Privacy Policy - Terms of Use

Google